Sulfonylureas (SUs) provide an efficacious first-line treatment in patients with hepatocyte nuclear factor 1α (HNF1A) diabetes, but SUs have limitations due to risk of hypoglycemia. Treatment based on the incretin hormones glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide 1 (GLP-1) is characterized by their glucose-dependent insulinotropic actions without risk of hypoglycemia.
May 23, 2025 -A Bayesian network meta-analysis was utilized to integrate direct and indirect evidence, facilitating a comparative ranking of various SGLT2 inhibitors—canagliflozin (CANA), ipragliflozin (IPRA), empagliflozin (EMPA), remogliflozin (REMO), licogliflozin (LICO), and dapagliflozin (DAPA)—as well as one GLP-1 receptor agonist—semaglutide (SEMA)—and a sulfonylurea—glimepiride (GLIM)—with respect to their efficacy and safety profiles.
Moving forward, it's essential to keep these visual contexts in mind when discussing Overcoming Glp-1 Resistance With Sulfonylureas.
In persons with KCNJ11 mutations, the Kir6.2- subunit of the KATP channel is defective and closure of the channel requires treatment with sulfonylurea, which binds to the SUR1-subunit of the channel. GLP-1 receptor agonists potentate an already active insulin secretion pathway by binding and activating the GLP-1 receptor.
4) suggesting that GLP-1R second-messenger activation by the GLP-1/Glb was not impaired but inhibitory sensitization of the KATP complex mediated by actors downstream of cAMP was. Previous data have also shown that interaction of sulfonylureas with exchange protein directly activated by cAMP 2 isoform A (Epac2A)/Rap1 signaling is crucial for combinatorial incretin-sulfonylurea augmentation of insulin secretion (46, 47).
